Moreover, the presence of BRAF mutations (BRAF (+)), despite not impacting recurrence-free survival from diagnosis of primary melanoma (stage I/II) to metastases development (stage IV) compared to BRAF WT patients, they do have a negative impact on median overall survival (OS) of patients who are newly diagnosed, untreated and with metastatic disease, since in BRAF (+) patients the OS is 5.7 months and for BRAF WT it is 8.5 months (Long et al., 2011). Here, BRAF is linked to metastatic neoplasm.